Reuters Health Report

Click to View in Browser 05/16/2014 U.S. regulator rejects Novartis heart failure drug ZURICH (Reuters) - U.S. health regulators turned down an application to approve Novartis' experimental heart failure drug due to insufficient evidence that it improves symptoms, the Swiss drugmaker said on Friday. Early promise, and caution, in measles virus cancer therapy NEW YORK (Reuters Health) - Mayo Clinic researchers stirred excitement on Thursday by saying they had treated a patient's blood cancer with a specially engineered measles virus, but even scientists involved in the work caution the response does not prove they have a cure. Global life expectancy rises again, but new challenges loom GENEVA (Reuters) - Average life expectancy has risen globally to 73 years for a girl born in 2012 and 68 for a boy following successes in fighting diseases and child mortality, the World Health Organization said on Thursday. Fitness linked to lower death risk in older men NEW YORK (Reuters Health) - No matter what age a man is, cardiovascular fitness may buy him more years of life, according to a new U.S. study of men over 70 with high blood pressure. Promising cancer drug data helps AstraZeneca in Pfizer fight (Reuters) - New data showing an experimental AstraZeneca lung cancer drug shrank tumors in more than half of patients gave the British group fresh ammunition to argue that Pfizer's takeover offer undervalues it substantially. Eli Lilly loses UK Alimta patent case to Actavis LONDON (Reuters) - Eli Lilly and Co LLY.N has lost a patent case in the English High Court over its blockbuster Alimta lung cancer drug to generic drugmaker Actavis Plc ACT.N, dealing a blow to the U.S. drugmaker's future sales hopes. Kamada's lead drug in development fails key trial (Reuters) - Israel-based drugmaker Kamada Ltd said its experimental drug failed in a key trial to treat an inherited condition that raises the risk of lung and liver disease. U.S. FDA lowers starting dose of sleep drug Lunesta over safety (Reuters) - U.S. health regulators on Thursday said they required a label change for the sleep drug Lunesta to cut the recommended starting dose over concerns it could impair alertness in some people the following morning. Muscle pain not well defined in most statin studies NEW YORK (Reuters Health) - Studies evaluating cholesterol-lowering drugs might find more muscle problems if they did a better job of defining and asking about muscle pain, suggests a new review. 'Exercise snacks' may help control blood sugar NEW YORK (Reuters Health) - Short bursts of intense exercise before meals may help control blood sugar spikes better than one longer, less intense session, suggests a new small study. Related Video Magic carpet lights the way for informative floors Antarctic ice loss "passed the point of no return": scientists The latest Reuters articles on M&A, IPOs, private equity, hedge funds and regulatory updates delivered to your inbox each day. Register Today   A daily digest of breaking business news, coverage of the US economy, major corporate news and the financial markets. Register Today   » MORE NEWSLETTERS

- 3 Times Square New York, NY 10036 USA © Copyright 2010 Thomson Reuters Ensure delivery of Reuters Newsmails, add mail@nl.reuters.com to your address book. Details Subscribe to other Reuters newsletters. Unsubscribe from this newsletter. Follow us on Twitter Friend us on Facebook Forward to a friend